Photos: Shutterstock
August 22, 2023 07:20 AM EDT
Deals
Pharma
In Focus

In­ver­sa­go was work­ing to­ward a po­ten­tial 2024 IPO, but No­vo’s in­ter­est won out. CB1 biotechs hope to ride the wave

Kyle LaHucik

Senior Reporter

Be­fore We­govy drug­mak­er No­vo Nordisk swept in to buy In­ver­sa­go Phar­ma for up to $1.075 bil­lion ear­li­er this month, the small Cana­di­an biotech had been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times